Serologic Profiles in Myasthenia Gravis

Written by Margaret Anne Rockwood | Last updated March 13, 2026
Medically reviewed by Nizar Souayah, MD

A defining feature of MG is the presence of serum autoantibodies targeting critical components of the neuromuscular junction (NMJ). Traditionally, MG was classified simply as ocular versus generalized, but modern approaches integrate antibody status with demographic and thymic features.

Classifying MG subtypes by serologic profile—in addition to clinical features—can mean the difference between early damage control versus the risks of NMJ damage that come with delay.

Even so, severity and symptom distribution remain primarily assessed clinically and with electrophysiologic studies rather than by antibody titer level alone.

Subtypes in MG

Classification of MG based on serologic profiles has transformed our understanding of the disease and improved personalized care. The major subtypes—AChR, MuSK, and LRP4 antibody–associated MG—differ not only in molecular pathogenesis, but also in clinical presentation, prognosis, and therapeutic response, making high-sensitivity cell-based assays (CBAs) essential for effective diagnosis and management.

Testing for MG antibodies is highly specific, but variably sensitive, with cell-based assays providing the greatest diagnostic yield. Seronegativity does not exclude MG, and electrophysiologic testing—particularly single fiber EMG—remains essential in antibody-negative cases.

Sensitivity is reported by antibody subtype, whereas specificity is defined relative to non-MG controls rather than MG subgroups. Statistics are based on CBAs versus radioimmunoassay (RIA). Apparent ‘low sensitivity’ at the population level often reflects subtype rarity, whereas within specific subtypes, CBAs demonstrate higher true assay sensitivity.

1. AChR Antibody-Positive MG
   Approximately 80–85% of generalized MG patients and 50-70% of ocular MG cases are AChR-antibody positive (AChR+). In patients with this subtype, antibodies bind to the nicotinic acetylcholine receptor (nAChR) at the postsynaptic membrane of the NMJ. Typically, these antibodies are of the IgG1 and IgG3 subclasses. AChR antibody titers correlate poorly with clinical severity.

2. MuSK Antibody-Positive MG
   A smaller subset (around 5–8%) of MG patients have antibodies against muscle-specific kinase (MuSK), a receptor tyrosine kinase (which is also an enzyme) that is critical for maintaining NMJ function and AChR clustering.MuSK antibodies are often IgG4 antibodies which generally do not activate the destructive complement as IgG1 and IgG3 antibodies do in AChR+. Instead, they interfere with the agrin–LRP4–MuSK signaling complex, impairing the clustering of AChRs, despite relatively preserved receptor density.

3. LRP4 Antibody-Positive MG
   In a subset (approximately 1–5%) of MG patients who are negative for both AChR and MuSK antibodies (double-negative), low-density Lipoprotein Receptor-related Protein 4 (LRP4) may be the target antigen. LRP4 is a receptor for agrin and is essential for MuSK activation and downstream AChR clustering. Antibodies against LRP4 may also exhibit functional cross-reactivity within the agrin–LRP4–MuSK signaling complex. Their functional overlap may explain clinical similarities between LRP4-positive MG and MuSK-associated disease, despite targeting different antigens.

4. Other Autoantibodies
   Additional antibodies have been described in MG, including those against agrin, titin, ryanodine receptor, and others. These are less common and often detected in specific clinical contexts. These additional markers require specialized assays and are not routinely tested outside of research settings.

• • Titin antibodies may be associated with thymoma, late onset MG and more severe generalized disease.
  • Agrin antibodies, though rarer, may co-occur with LRP4 antibodies and contribute to impaired NMJ signaling.
  • Ryanodine receptor (RyR) antibodies may appear in thymoma-associated MG, but are not specific.

These additional markers require specialized assays and are not routinely tested outside of research settings.

Seronegative Myasthenia Gravis

When a patient lacks detectable antibodies against AChR, MuSK, and LRP4, they are classified as having seronegative MG. However, this may represent the small percentage who may have detectable antibodies later, due to improved sensitivity of the assays or as new antibodies are characterized.

Modern cell-based assays have increased sensitivity for low-titer antibodies and have reclassified some previously seronegative patients. In true seronegative MG, electrophysiological testing such as single-fiber EMG (SFEMG), repetitive nerve stimulation (RNS) and clinical response to AChR inhibitors remain important for diagnosis.

Ranges vary with muscle selection and technique. 

Assay Sensitivity and Specificity

Ordering Lab Assays

Once a clinician has confirmed a symptom match with MG and excluded mimics, serologic testing is the most definitive next step to classify the type of MG. Improved assay technology enables fairly high sensitivity and high specificity in these lab tests.

Clinicians may want to order dual assays (usually RIA + CBA) to improve sensitivity, particularly in borderline, early, or atypical cases. Clinical context should always guide testing — a negative antibody test does not rule out MG, and electrophysiologic studies (SFEMG, RNS) remain essential.

Dual assays are particularly indicated with:

1. Borderline / low-titer antibodies
2. Double-seronegative patients
3. Rare antibody subtypes (LRP4, agrin, titin)
4. High clinical suspicion despite a negative first test

They are not usually done where typical generalized AChR-positive MG is suspected, because assay sensitivity is already very high (~90–98%).

Reported sensitivities reflect ranges derived from published cohorts using contemporary cell-based assays; for less common antibody subtypes (particularly LRP4), sensitivity estimates vary by assay methodology and cohort definition, and the absence of an independent gold standard limits precise determination of true subtype-specific sensitivity.

Sample Physician’s Order

1. Serologic Testing – Antibody Panel

• AChR Ab – binding & blocking (RIA and CBA if available)
• MuSK Ab – include CBA
• LRP4 Ab – CBA if clinically indicated (double seronegative)
• Optional: Agrin Ab, Titin Ab, RyR Ab (indicated only in research or specific clinical context)

2. Electrophysiologic Studies

• Single-Fiber EMG – most sensitive test for NMJ disorder
• Repetitive Nerve Stimulation – adjunctive diagnostic test

3. Imaging

• Chest CT/MRI – evaluate for thymoma or thymic hyperplasia

4. Baseline Labs Before Immunotherapy

• CBC, CMP
• Thyroid panel (TFTs)
• ESR/CRP (optional)

      Notes:

• If the initial antibody panel is negative, but clinical suspicion persists, repeat testing with CBA or send to a reference laboratory.
• Document fatigable weakness and coordinate SFEMG and imaging interpretation.

Clinical Implications of Testing

Serologic subtyping in MG has important clinical relevance:

1. AChR+ MG may respond well to conventional immunosuppressants and thymectomy.
2. MuSK MG often has a more refractory course and may require B-cell–targeted therapies.
3. LRP4 MG tends to have milder disease, but overlapping syndromes and combined antibodies can influence severity.

Antibody profiles also guide expectations for thymic pathology and the likelihood of thymoma (a slow-growing lesion), which is more common in AChR-positive patients.

As more sensitive assays and novel antibody targets emerge, serologic classification will likely play an even greater role in guiding targeted therapies and predicting disease course, while pursuing a goal of increasingly personalized treatment.

References

1. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. Dresser, L, Wlodarski R., Rezania K., Soliven B. J Clin Med. 2021;10(11):2235.
2. Autoantibodies in myasthenia gravis. Fichtner, M. L., et al. Int Rev Neurobiol. 2025;182:89-119.
3. Functional signature of LRP4 antibodies in myasthenia gravis. Chuquisana, O., et. al. Neurology: Neuroimmunology & Neuroinflammation. 2024.
4. Development and application of a cell-based assay for detection of LRP4 antibodies in myasthenia gravis. Chung, H. Y., et al. Journal of Clinical Neurology.
5. Myasthenia gravis: the future is here. Kaminski, H. J. Journal of Clinical Investigation.
6. Antibodies against LRP4 induce myasthenia gravis. Shen, C., et al. J Clin Invest. 2013;123(12):5190-5202.
7. Clinical characteristics of anti-AChR MG with anti-LRP4 or anti-Titin antibody. Chen. Y., et al. Front Neurol.